

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/519,805
		Filing Date	December 29, 2004
		First Named Inventor	Brad St. CROIX et al.
		Art Unit	1643
		Examiner Name	M. Natarajan
		Attorney Docket Number	001107.00527
Sheet	1	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		U.M. WEWER ET AL., "Osteonectin/SPARC/BM-40 in Human Decidua and Carcinoma, Tissues Characterized by De Novo Formation of Basement Membrane," American Journal of Pathology, August 1988, Vol. 132, No. 2, pp. 345-355	
		J.E. SCHNITZER ET AL., "Antibodies to SPARC Inhibit Albumin Binding to SPARC, gp60, and Microvascular Endothelium," The American Physiological Society, 1992, pp. H1872-1879	
		S. SANGALETTI ET AL., "Matricellular Proteins at the Crossroad of Inflammation and Cancer," Cancer Letters, 2008, pp. 1-9	
		S.A. REMPEL ET AL., "SPARC: A Potential Diagnostic Marker of Invasive Meningiomas," Clinical Cancer Research, February 1999, Vol. 5, pp. 237-241	
		M.P. COLOMBO ET AL., "Down-Regulation of SPARC/Osteonectin/BM-40 Expression in Methylcholanthrene-Induced Fibrosarcomas and in Kirsten-MSV Transformed Fibroblasts," Eur. J. Cancer, 1991, Vol. 27, No. 1, pp. 58-62	
		S. ARNOLD ET AL., "Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC," Exp. Biol. Med. (Maywood), July 2008, pp. 860-873	
		M.P. COLOMBO ET AL., "Osteonectin Transcript and Metastatic Behavior in v-Ki-ras Transformed Fibroblasts," Int. J. Cancer, 1989, pp. 76-77	
		H. PORTE ET AL., "Neoplastic Progression of Human Colorectal Cancer is Associated with Overexpression of the Stromelysin-3 and BM-40/SPARC Genes," Int. J. Cancer, 1995, pp. 70-75	
		C. LUSSIER ET AL., "Expression of SPARC/Osteonectin/BM40 in the Human Gut: Predominance in the Stroma of the Remodeling Distal Intestine," Journal of Cellular Biochemistry, 2001, pp. 463-476	
		H. SAGE ET AL., "Characterization of a Novel Serum Albumin-Binding Glycoprotein Secreted by Endothelial Cells in Culture," The Journal of Biological Chemistry, March 25, 1984, Vol. 259, No. 6, pp. 3993-4007	
		P.L. PORTER ET AL., "Distribution of SPARC in Normal and Neoplastic Human Tissue," The Journal of Histochemistry and Cytochemistry, 1995, Vol. 43, No. 8, pp. 791-800	
		S.A. REMPEL, "SPARC Modulates Cell Growth, Attachment and Migration of U87 Glioma Cells on Brain Extracellular Matrix Proteins," Journal of Neuro-Oncology, 2001, pp. 149-160	
		S.A. REMPEL, "SPARC: A signal of Astrocytic Neoplastic Transformation and Reactive Response in Human Primary and Xenograft Gliomas,"	

Examiner Signature	/Meera Natarajan/	Date Considered	12/22/2008
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/519,805
		Filing Date	December 29, 2004
		First Named Inventor	Brad St. CROIX et al.
		Art Unit	1643
		Examiner Name	M. Natarajan
		Attorney Docket Number	001107.00527
Sheet	2	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		M.L. IRUELA-ARISPE ET AL., "Differential Expression of Extracellular Proteins is Correlated with Angiogenesis <i>in Vitro</i> ," Laboratory Investigation, 1991, Vol. 64, No. 2, pp. 174-186	
		M.F. YOUNG ET AL., "Osteonectin mRNA: Distribution in Normal and Transformed Cells," Nucleic Acids Research, 1986, Vol. 14, No. 11, pp. 4483-4498	
		S.C. MOK ET AL., "SPARC, An Extracellular Matrix Protein with Tumor-Suppressing Activity in Human Ovarian Epithelial Cells," Oncogene, 1996, pp. 1895-1901	
		C. TIRUPPATHI ET AL., "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from Vascular Endothelial Cells," Proc. Natl. Acad. Sci., January 1996, Vol. 93, pp. 250-254	
		A. BELLAHCENE ET AL., "Increased Expression of Osteonectin and Osteopontin, Two Bone Matrix Proteins, in Human Breast Cancer," American Journal of Pathology, January 1995, Vol. 146, No. 1, pp. 95-100	
		O.L. PODHAJEC ET AL., "Comparative Expression of the SPARC and Stromelysin-3 Genes in Mammary Tumours," The Breast, 1996, pp. 13-20	
		C. SCHULTZ ET AL., "Secreted Protein Acidic and Rich in Cysteine Promotes Glioma Invasion and Delays Tumor Growth <i>in Vivo</i> ," Cancer Research, November 1, 2002, pp. 6270-6277	
		M.J. REED ET AL., "SPARC and the Extracellular Matrix: Implications for Cancer and Wound Repair," Current Topics in Microbiology and Immunology, 1996, Vol. 213, pp. 81-94	
		J.D. GRAHAM ET AL., "Expression of Osteonectin mRNA in Human Breast Tumours is Inversely Correlated with Oestrogen Receptor Content," European Journal of Cancer, 1997, Vol. 33, No. 10, pp. 1654-1660	
		E. A. EVERITT ET AL., "Expression of SPARC is Correlated with Altered Morphologies in Transfected F9 Embryonal Carcinoma Cells," Experimental Cell Research, 1992, Vol. 199, pp. 134-146	
		P. VAJKOCZY ET AL., "Targeting Angiogenesis Inhibits Tumor Infiltration and Expression of the Pro-Invasive Protein SPARC," Int. J. Cancer, 2000, Vol. 87, pp. 261-268	
		P. M. MENON ET AL., "A Study of SPARC and Vitronectin Localization and Expression in Pediatric and Adult Gliomas: High SPARC Secretion Correlates with Decreased Migration on Vitronectin," International Journal of Oncology, 2000, Vol. 17, pp. 683-693	
		C. KUPPRION ET AL., "SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells," The Journal of Biological Chemistry, November 6, 1998, Vol. 273, No. 45, pp. 29635-29640	

Examiner Signature	/Meera Natarajan/	Date Considered	12/22/2008
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/519,805
		Filing Date	December 29, 2004
		First Named Inventor	Brad St. CROIX et al.
		Art Unit	1643
		Examiner Name	M. Natarajan
		Attorney Docket Number	001107.00527
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		D. W. NYMAN ET AL., "Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients with Advanced Nonhematologic Malignancies," Journal of Clinical Oncology, November 1, 2005, Vol. 23, No. 31, pp. 7785-7793	
		Y. W. KIM ET AL., "Expression of Osteopontin and Osteonectin in Breast Cancer," J. Korean Med. Sci., 1998, Vol. 13, pp. 652-657	
		W. A. GOLEMBIESKI ET AL., "cDNA Array Analysis of SPARC-Modulated Changes in Glioma Gene Expression," Journal of Neuro-Oncology, 2002, Vol. 60, pp. 213-226	
		M. YAMANAKA ET AL., "Analysis of the Gene Expression of SPARC and its Prognostic Value for Bladder Cancer," The Journal of Urology, December 2001, Vol. 166, pp. 2495-2499	
		M. F. LEDDA ET AL., "The Role of SPARC Gene in the Tumorigenic Capacity of Human Melanoma Cells," Medicina, 1996, Vol. 56, Issue 1, pp. 51-54	
		S. V. VADLAMURI ET AL., "SPARC Affects Glioma Cell Growth Differently When Grown on Brain ECM Proteins in Vitro Under Standard Versus Reduced-Serum Stress Conditions," Neuro-Oncology, October 2003, pp. 245-254	
		E. GRUNDMANN ET AL., "New Aspects of Cell Biology in Osteosarcoma," Path. Res. Pract., 1995, Vol. 191, pp. 563-570	
		J. MARX, "Gene Expression," Science, August 18, 2000, Vol. 289, Issue 5482, pp. 1121-1122	

Examiner Signature	/Meera Natarajan/	Date Considered	12/22/2008
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.N./